Skip to main content

Table 4 Changes in study outcome measures according to echocardiography, mean ± SD and median (Q3–Q1)

From: Effect of once versus twice intracoronary injection of allogeneic-derived mesenchymal stromal cells after acute myocardial infarction: BOOSTER-TAHA7 randomized clinical trial

 

Control (n = 25)

Single intervention (n = 20)

Repeated intervention (n = 20)

P value

EF baseline

35.73 ± 3.59

36 (38–32)

34.75 ± 1.97

34 (37–33.3)

33.85 ± 1.67a

33 (36–32.3)

0.066

EF final

44.27 ± 8.65

43 (49–39)

50 ± 10.21

49 (61–40)

53 ± 12.11a

52 (64–43)

0.006

EF change

8.53 ± 9.39

8 (15–3)

15.25 ± 8.35

15 (24–6.8)

19.25 ± 9.12a

19 (28–10.8)

 < 0.001

LVEDD baseline

50.92 ± 6.16

51 (56–44.8)

54.5 ± 5.87

55 (60.5–48)

55.4 ± 7.65a

56.5 (62.5–49)

0.04

LVEDD final

55.8 ± 5.23

57 (59–51)

57.25 ± 11.27

52.5 (70.3–49)

54.25 ± 10.67a

49.5 (67.3–46)

0.031

LVEDD change

5.46 ± 7.37

6 (9.5–(− 0.3))

2.75 ± 10.96

3.5 (14–(− 9.3))

− 1.15 ± 11.59

0 (12–(− 14))

0.099

LVESD baseline

36.92 ± 6.58

37 (41.3–31.5)

36.75 ± 6.7

37.5 (43.5–29.3)

39.65 ± 6.96

43 (45–31.5)

0.317

LVESD final

42.53 ± 8.32

38 (47–37)

39 ± 17.74

34 (60–23)

35 ± 16.94

30 (56–19)

0.083

LVESD change

6.62 ± 7.9

2 (10–1.8)

2.25 ± 14.83

1.5 (18.8–(− 13.5))

− 4.65 ± 14.55a

− 11 (12.5–(− 19.3))

0.01

LVEDV baseline

98.08 ± 23.55

101.5 (116.3–78.5)

118.25 ± 22.61

123.5 (139–92.3)

123.25 ± 21.91a

128.5 (144–128.5)

0.002

LVEDV final

101.33 ± 23.94 103 (125–78)

121.75 ± 50.33 114 (177.3–74)

116.75 ± 48.93

109 (172.3–69)

0.19

LVEDV change

4.58 ± 21.15

0.5 (28.8–(− 15.5))

3.5 ± 3.23

1 (51.3–(− 41.75))

− 6.5 ± 4.32

− 9 (41.3–(− 51.8))

0.39

LVESV baseline

63.25 ± 14.54

65.5 (73.5–49.7)

77.31 ± 15.91

79.4 (92.8–59.8)

81.81 ± 16.18a

83.8 (97.6–64)

0.003

LVESV final

56.8 ± 16.49

62.1 (69–40.3)

65.59 ± 38.28

58.1 (108.2–30.4)

59.59 ± 36.28

52.3 (100–26.4)

0.392

LVESV change

− 5.68 ± 16.62

− 5.1 (4.6–(− 20.1))

− 11.72 ± 5.18

− 16.4 (24–(− 42.7))

− 22.22 ± 9.26

− 26.7 (11.2–(− 51.11))

0.015

GLS baseline

− 9.84 ± 2.6

− 9.5 (− 8.6–(− 11))

− 9.28 ± 2.34

− 10.1 (− 6.5–(− 11.2))

− 8.28 ± 1.95

− 9.1 (− 5.5–(10.2))

0.092

GLS final

− 14.13 ± 2.77

− 14.2 (− 13–(− 16.5))

− 16.05 ± 3.85

− 16.5 (− 11.7–(− 19.9))

− 18.05 ± 3.75a

− 18.6 (− 13.7–(− 21.9))

0.007

GLS change

− 3.92 ± 2.35

− 3.7 (− 2.9–(− 4.81))

− 6.77 ± 3.05a

− 7.4 (− 3.3–(− 9.6))

− 9.77 ± 3.65a

− 10.4 (− .3–(− 12.6))

 < 0.001

  1. aSignificant difference with the control group on the post hoc test
  2. bSignificant difference with the single intervention group on the post hoc test
  3. EF ejection fraction, LVEDD left ventricular end-diastolic diameter, LVESD left ventricular end-systolic diameter, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, GLS global longitudinal strain